Statins and plaque stability.
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are now the standard of care for patients with hypercholesterolaemia. This class of inhibitors, known as 'statins', has been shown to reduce cardiovascular morbidity and mortality. Accumulating data demonstrates a variety of mechanisms in which HMG-CoA reductase inhibition benefits the cardiovascular system. This review will discuss the pharmacology, clinical trials, and mechanisms, besides lipid lowering, of statin therapy.
Arteriosclerosis↗